scholarly journals Drug‐induced QTc interval prolongation in PCR‐positive non‐ICU COVID‐19 patients with diverse findings on chest computed tomography

2021 ◽  
Author(s):  
Ferhat Ozyurtlu ◽  
Nurullah Cetin ◽  
Veysel Yavuz
Keyword(s):  
Computed Tomography ◽  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Chest Computed Tomography ◽  
Qtc Interval Prolongation

Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development

2008 ◽  
Vol 44 (4) ◽  
pp. 494-500 ◽  
Author(s):  
Giuseppe Curigliano ◽  
Gianluca Spitaleri ◽  
Howard J. Fingert ◽  
Filippo de Braud ◽  
Cristiana Sessa ◽  
...  
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qtc Interval Prolongation ◽  
Anticancer Drug Development

Translating the gap in the evaluation of drug-induced QTc-interval prolongation from in vivo to the clinic

2014 ◽  
Vol 70 (3) ◽  
pp. 324
Author(s):  
Vincent F.S. Dubois ◽  
Piet van der Graaf ◽  
Derek Leishman ◽  
David Gallacher ◽  
Nick McMahon ◽  
...  
Keyword(s):  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qtc Interval Prolongation

scholarly journals Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans

2015 ◽  
Vol 33 (1) ◽  
pp. 40-51 ◽  
Author(s):  
V. F. S. Dubois ◽  
◽  
W. E. A. de Witte ◽  
S. A. G. Visser ◽  
M. Danhof ◽  
...  
Keyword(s):  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Cynomolgus Monkeys ◽  
Interspecies Differences ◽  
Qtc Interval Prolongation

scholarly journals The Effect of Chest Computed Tomography Findings on QT Interval in Patients with COVID 19 Using Drugs That May Prolong QT Interval

2021 ◽  
Author(s):  
Ferhat Özyurtlu ◽  
Nurullah Cetin ◽  
Veysel Yavuz
Keyword(s):  
Computed Tomography ◽  
Heart Rate ◽  
Qt Interval ◽  
Chest Ct ◽  
Qtc Interval ◽  
Interval Prolongation ◽  
Chest Computed Tomography ◽  
Qt Interval Prolongation ◽  
Ct Findings ◽  
Low Sensitivity

Background Some drugs used in the treatment of coronavirus disease 2019 (COVID-19) are likely to increase the risk of QT interval prolongation and related arrhythmias or death. Due to the low sensitivity of the reverse transcriptase-polymerase chain reaction (RT-PCR) test, chest computed tomography (CT) imaging is being used for COVID-19 diagnostic correlation and to evaluate whether there is pneumonic involvement in the lung. Objective In this study, we aimed to compare whether there was a difference in terms of QT interval prolongation and effect on heart rate in COVID-19 patients based on their chest CT findings and drug treatment regimes. Methods This was a single-center retrospective cohort study of non-intensive care unit (ICU) patients hospitalized . A total of 344 patients with a mean age of 46.34 ± 17.68 years were included in the study (56.1% men). Patients were divided into four groups according to their chest CT results as having typical, atypical, indeterminate, or no finding of pneumonic involvement. Mean QTc intervals and heart rates calculated from electrocardiograms at admission and after treatment were compared. Results There were no significant differences between groups with regards to age, gender, and body mass index (BMI). There were also no significant differences between the groups in terms of mean QTc interval values upon admission (p:0.127) or after treatment (p:0.205). Heart rate values were similar among the groups as well, with no significant differences in mean heart rate on admission (p:0.648) and post-treatment (p:0.229) ECGs. Conclusion This study has demonstrated finding of COVID-19 infection based on chest CT does not affect QT interval prolongation and bradycardia in non-ICU COVID-19 patients. There is a need for additional larger studies investigating the effect of chest CT findings on QT interval prolongation and bradycardia in COVID-19 patients.

SSRIs and QT interval prolongation management. A review

2017 ◽  
Vol 41 (S1) ◽  
pp. S750-S750
Author(s):  
A. Ballesteros ◽  
H. Saiz ◽  
Á.S. Rosero ◽  
A. Portilla ◽  
L. Montes ◽  
...  
Keyword(s):  
Risk Factors ◽  
Qt Interval ◽  
Future Research ◽  
Current Debate ◽  
Qtc Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Cross Sectional ◽  
Qt Interval Prolongation ◽  
Qtc Interval Prolongation

IntroductionIn 2011, the FDA issued an alert recommending not to prescribe citalopram high doses, due to QT prolongation risk. We explored the clinical background of QT interval prolongation related to serotonin selective reuptake inhibitors (SSRI) use and the clinical implications of safety issues.MethodologyA review was conducted to clarify the mechanisms associated with the occurrence of TdP when using SSRI and investigating therapeutic measures to avoid/minimize these effects. The literature search was conducted in PubMed data reviewing articles between 2001 and 2016.Results(1) Related to risk factors/intraclass differences: risk factors are increase in QTc interval ≥60 ms from the pretreatment value, advanced age, female sex, acute myocardial infarction and electrolytic abnormalities among others. Citalopram appears more likely than others to induce this phenomenon but its importance is under current debate. (2) Related to dose: drug-induced QTc interval prolongation and TdP was associated to citalopram in doses > 40 mg/day. However, psychotropic drug-induced sudden cardiac death may be an outlier in the absence of identified risk factors for QTc interval prolongation and TdP. (3) Related to poly-pharmacy/management: there is an additive effect when using SSRI and antipsychotics (EKG control is recommended in those cases). Cross-sectional studies showed that SSRI use was not associated with QT interval prolongation. This could be explained by the EKG intra-intersubject variability.ConclusionsThere is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict TdP. Future research needs to improve its precision to better understand the factors that facilitate/attenuate that progression. Clarifying this may lead to a safer SSRI use.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice

2016 ◽  
Vol 11 (1) ◽  
pp. 86-98 ◽  
Author(s):  
Guillermo A. Keller ◽  
Paulino A. Alvarez ◽  
Marcelo L. Ponte ◽  
Waldo H. Belloso ◽  
Claudia Bagnes ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Qtc Interval ◽  
Clinical Factors ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qtc Interval Prolongation

Dextropropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels

2018 ◽  
Vol 14 (5) ◽  
pp. 335-344 ◽  
Author(s):  
Guillermo Alberto Keller, MD, PhD ◽  
Cecilia Villa Etchegoyen, MD ◽  
Nicolás Fernandez, PharmD, PhD ◽  
Nancy Mónica Olivera, PharmD, PhD ◽  
Patricia Noemí Quiroga, PharmD, PhD ◽  
...  
Keyword(s):  
Public Hospital ◽  
Outcome Measure ◽  
General Ward ◽  
Qtc Interval ◽  
Plasma Drug ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qt Interval Prolongation ◽  
Qtc Interval Prolongation ◽  
Therapeutic Doses

Objective: To evaluate frequency and risk factors for dextropropoxyphene-induced QT-interval prolongation in the clinical setting.Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals.Setting: General ward of a public hospital of metropolitan Buenos Aires.Patients, Participants: Ninety-two patients with indication of receiving dextropropoxyphene for analgesic purposes were included consecutively. All patients finished the study.Interventions: All patients were monitored with electrocardiographic controls (previous to drug administration and during steady state) to diagnose and quantify changes in the duration of the QTc interval.Main Outcome Measure: Frequency of drug-induced QTc interval prolongation, QTc interval correlation with plasma drug, and metabolite levels.Results: Ninety-two patients were studied (50 percent males). All patients received a (mean ± SD [range]) dextropropoxyphene dose of 125 ± 25[100-150] mg/d. Dextropropoxyphene and norpropoxyphene concentrations were 112 ± 38[45-199] and 65 ± 33[13-129] ng/mL, respectively. The intra-treatment QTc interval was 450 ms in only one patient (only with the Hodge correction). There were no cases of QTc 500 ms, and there were no significant differences in the results considering different correction formulas (Bazzet, Fridericia, Framingham, Hodges). Dextropropoxyphene concentrations correlated with QTc (R 0.45) interval and ΔQTc (R 0.52-0.87), whereas norpropoxyphene correlation was even greater for QTc (R 0.40-0.64) and ΔQTc (R 0.47-0.92). Depending on the QTc correction formula, eight patients presented ΔQTc 30 ms and one patient with ΔQTc 60 ms. No patient presented arrhythmia during the study.Conclusions: The authors did not observe a relationship between dextropropoxyphene and QTc interval prolongation at the therapeutic doses used in Argentina.

Sign in / Sign up

Export Citation Format

Share Document